CR20250040A - Inhibidores de la proteasa principal de sars-cov2 - Google Patents

Inhibidores de la proteasa principal de sars-cov2

Info

Publication number
CR20250040A
CR20250040A CR20250040A CR20250040A CR20250040A CR 20250040 A CR20250040 A CR 20250040A CR 20250040 A CR20250040 A CR 20250040A CR 20250040 A CR20250040 A CR 20250040A CR 20250040 A CR20250040 A CR 20250040A
Authority
CR
Costa Rica
Prior art keywords
cov2
sars
protease inhibitors
main protease
main
Prior art date
Application number
CR20250040A
Other languages
English (en)
Inventor
Eda Y Canales
Gregory F Chin
Veldhuizen Joshua J Van
Weng K Chang
Scott E Lazerwith
Jessica L Mckinley
Jason K Perry
Stephen E Ammann
Christopher J Swank
Xinpei Cai
Devan Naduthambi
Scott D Schroeder
Kevin X Rodriguez
Henok H Kinfe
Michael R Mish
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CR20250040A publication Critical patent/CR20250040A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripción se relaciona con compuestos de la Fórmula I: y sales farmacéuticamente aceptables de estos, composiciones farmacéuticas de estos, útiles en el tratamiento para tratar infecciones virales, por ejemplo, infecciones por <em>coronaviridae</em>.
CR20250040A 2022-08-05 2023-08-04 Inhibidores de la proteasa principal de sars-cov2 CR20250040A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263370629P 2022-08-05 2022-08-05
US202263375522P 2022-09-13 2022-09-13
US202263476359P 2022-12-20 2022-12-20
US202363482750P 2023-02-01 2023-02-01
US202363486156P 2023-02-21 2023-02-21
US202363508350P 2023-06-15 2023-06-15
PCT/US2023/071744 WO2024031089A1 (en) 2022-08-05 2023-08-04 Sars-cov2 main protease inhibitors

Publications (1)

Publication Number Publication Date
CR20250040A true CR20250040A (es) 2025-03-18

Family

ID=87889341

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250040A CR20250040A (es) 2022-08-05 2023-08-04 Inhibidores de la proteasa principal de sars-cov2

Country Status (16)

Country Link
US (3) US20240239807A1 (es)
EP (1) EP4565574A1 (es)
JP (1) JP2025525948A (es)
KR (1) KR20250046274A (es)
CN (1) CN119731159A (es)
AU (1) AU2023320566A1 (es)
CA (1) CA3263377A1 (es)
CL (2) CL2025000338A1 (es)
CO (1) CO2025001287A2 (es)
CR (1) CR20250040A (es)
DO (1) DOP2025000019A (es)
IL (1) IL318656A (es)
MX (1) MX2025001407A (es)
PE (1) PE20250877A1 (es)
TW (1) TW202408511A (es)
WO (1) WO2024031089A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023283256A1 (en) 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds
AU2023303408A1 (en) 2022-07-06 2024-12-19 Aligos Therapeutics, Inc. Anti-viral compounds
CR20250040A (es) * 2022-08-05 2025-03-18 Gilead Sciences Inc Inhibidores de la proteasa principal de sars-cov2
US20250276979A1 (en) * 2024-02-07 2025-09-04 Gilead Sciences, Inc. Sars-cov2 main protease inhibitors
AU2025219283A1 (en) * 2024-02-07 2026-08-06 Gilead Sciences, Inc. Sars-cov2 main protease inhibitors

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284661A (en) 1990-02-22 1994-02-08 Takeda Chemical Industries, Ltd. Fused thiophene derivatives, their production and use
TW449600B (en) 1994-04-19 2001-08-11 Takeda Chemical Industries Ltd Condensed-ring thiophene derivatives, their production and use
US8030346B2 (en) 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
MX370976B (es) 2011-11-11 2020-01-10 Gilead Apollo Llc Inhibidores de acetil coa carboxilasa (acc) y usos de los mismos.
AR106472A1 (es) 2015-10-26 2018-01-17 Gilead Apollo Llc Inhibidores de acc y usos de los mismos
JP7254028B2 (ja) 2017-05-16 2023-04-07 アンジー ファーマスーティカル シーオー．，エルティーディー． ヒストンデアセチラーゼ（ｈｄａｃｓ）阻害剤
EP3875078A1 (en) * 2020-03-06 2021-09-08 Dompe' Farmaceutici S.P.A. Compounds for the treatment of covid-19
CN111440188B (zh) 2020-04-10 2022-03-08 江苏海悦康医药科技有限公司 一种瑞卢戈利(Relugolix)关键中间体的制备方法
CN112778310B (zh) 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
WO2021228762A1 (en) * 2020-05-11 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tmprss2 inhibitors for the treatment of lung viral infections
CN111875614B (zh) 2020-07-03 2022-04-29 东莞市东阳光新药研发有限公司 杂环基取代的噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮类化合物及其用途
CN111793078B (zh) 2020-07-03 2022-02-01 东莞市东阳光新药研发有限公司 双环含氮杂芳基取代的嘧啶二酮类化合物及其用途
CN111925379B (zh) 2020-07-31 2022-02-15 广东东阳光药业有限公司 含氮杂芳基取代的嘧啶二酮类化合物及其用途
CN111909168B (zh) 2020-07-31 2022-02-01 广东东阳光药业有限公司 含氮杂环基取代的嘧啶二酮类化合物及其用途
US11926645B2 (en) 2020-08-27 2024-03-12 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
CN112047957B (zh) 2020-09-09 2022-02-01 广东东阳光药业有限公司 取代的嘧啶二酮类化合物及其用途
CN113754679B (zh) 2020-09-09 2023-04-07 广东东阳光药业有限公司 取代的嘧啶二酮类化合物及其用途
WO2022067566A1 (zh) 2020-09-29 2022-04-07 广东东阳光药业有限公司 含有饱和含氧杂环基的嘧啶二酮类化合物及其用途
CN116438181B (zh) 2020-09-29 2025-01-17 广东东阳光药业股份有限公司 磺酰胺基取代的杂芳基嘧啶二酮类化合物及其用途
CN112142757B (zh) 2020-09-29 2022-02-15 广东东阳光药业有限公司 五元含氮杂芳基取代的嘧啶二酮类化合物及其用途
CN116370479B (zh) 2020-12-30 2024-02-13 南方科技大学 化合物atv014在制备用于治疗新冠病毒感染的产品中的用途
WO2022150962A1 (en) 2021-01-12 2022-07-21 Westlake Pharmaceutical (Hangzhou) Co., Ltd. Protease inhibitors, preparation, and uses thereof
WO2022224223A1 (en) * 2021-04-23 2022-10-27 Novartis Ag Compounds and compositions for the treatment of coronaviral related diseases
MA53521B1 (fr) 2021-05-12 2023-03-31 Univ Ibn Tofail Nouveaux composés inhibiteurs de la protéase mpro et de la réplication du sars-cov2, leurs formulations et applications
US20240261307A1 (en) 2021-05-28 2024-08-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibitors of sars-cov-2 viral replication and uses thereof
WO2022266368A1 (en) 2021-06-16 2022-12-22 The Cleveland Clinic Foundation Protease inhibitors and methods of use
WO2023283831A1 (zh) 2021-07-14 2023-01-19 上海药明康德新药开发有限公司 病毒主蛋白酶抑制剂及其制备方法和用途
WO2023004291A1 (en) 2021-07-19 2023-01-26 Baylor College Of Medicine Coronavirus main protease inhibitors and methods using same
UY39863A (es) 2021-07-22 2023-02-28 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus
WO2023034854A1 (en) 2021-08-31 2023-03-09 Pardes Biosciences, Inc. Crystalline inhibitors of cysteine proteases and methods of use thereof
CN115745960B (zh) 2021-09-02 2024-08-30 中国科学院上海药物研究所 一类含喹啉酮酰胺的化合物及其制备方法、药物组合物和用途
JP2024178473A (ja) 2021-09-03 2024-12-25 塩野義製薬株式会社 ウイルス増殖阻害活性を有する二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
WO2023036140A1 (zh) 2021-09-07 2023-03-16 上海齐鲁制药研究中心有限公司 3CLpro蛋白酶抑制剂
US20240400560A1 (en) * 2021-09-17 2024-12-05 Shionogi & Co., Ltd. Bicyclic heterocyclic derivative having viral growth inhibitory activity and pharmaceutical composition containing same
US12186309B2 (en) 2021-09-27 2025-01-07 The Governors Of The University Of Alberta RNA virus inhibitor compounds and uses thereof
AU2022353486A1 (en) 2021-09-28 2024-05-02 National University Corporation Hokkaido University Pharmaceutical composition containing triazine derivative
TW202330513A (zh) 2021-09-28 2023-08-01 加拿大商愛彼特生物製藥公司 )抑制劑及其使用方法
WO2023054759A1 (ko) 2021-09-30 2023-04-06 한국화학연구원 2-아미노퀴나졸린 유도체 및 이를 포함하는 항바이러스용 조성물
CN114957381B (zh) 2021-10-22 2026-04-17 广州谷森制药有限公司 新型氘代氰基类化合物、其制备方法、组合物及应用
CN116003509A (zh) 2021-10-22 2023-04-25 广州谷森制药有限公司 新型氘代苯并噻唑类化合物、其制备方法、组合物及应用
CN116003495A (zh) 2021-10-22 2023-04-25 广州谷森制药有限公司 新型氘代嘌呤核苷类化合物、其制备方法、组合物及其应用
JP7253866B1 (ja) 2021-11-24 2023-04-07 塩野義製薬株式会社 トリアジン誘導体を含有する経口投与する製剤
WO2023095860A1 (ja) 2021-11-26 2023-06-01 塩野義製薬株式会社 ３ｃｌプロテアーゼ阻害剤及びｃｏｖｉｄ－１９治療用薬剤を組み合わせることを特徴とするｃｏｖｉｄ－１９治療用医薬
CN114031626A (zh) 2021-12-09 2022-02-11 成都科圣原医药科技有限公司 一种瑞卢戈利的合成方法
CN116265440B (zh) 2021-12-16 2024-09-27 贵州大学 一种水杨酮拼接吡啶酮类化合物及其制备方法及应用
WO2023114428A1 (en) 2021-12-16 2023-06-22 Vir Biotechnology, Inc. Heterocycle derivatives for the treatment of disease
US20250074907A1 (en) 2021-12-22 2025-03-06 The Texas A&M University System Inhibitors of sars-cov-2
JP7273455B1 (ja) 2022-01-19 2023-05-15 塩野義製薬株式会社 新型コロナウイルス感染症治療用医薬
CN116514795A (zh) 2022-01-29 2023-08-01 齐鲁制药有限公司 3CLpro蛋白酶抑制剂的制备方法
WO2023155830A1 (zh) 2022-02-18 2023-08-24 南京明德新药研发有限公司 吡啶酮或嘧啶酮衍生物及其应用
CN116655606A (zh) 2022-02-18 2023-08-29 广州谷森制药有限公司 新型氘代三嗪类化合物、其制备方法、组合物及应用
WO2023158785A1 (en) 2022-02-21 2023-08-24 University Of Houston System Small molecules that treat or prevent viral infections
WO2023165459A1 (en) 2022-03-01 2023-09-07 Fochon Biosciences , Ltd. Compounds as sars-cov-2 inhibitors
JP2025510603A (ja) 2022-03-10 2025-04-15 湖北九康通生物医▲薬▼有限公司 トリアジン化合物、中間体、製造方法および用途
CN114539228A (zh) 2022-03-14 2022-05-27 药康众拓(江苏)医药科技有限公司 三嗪类化合物或其可药用盐、异构体、药物组合物和用途
CN116284133B (zh) 2022-03-24 2024-03-29 南京知和医药科技有限公司 一种新型六元杂环类衍生物及其药物组合物和用途
CN116891484A (zh) 2022-03-31 2023-10-17 江苏恒瑞医药股份有限公司 稠环类化合物、其制备方法及其在医药上的应用
CN116514784A (zh) 2022-04-01 2023-08-01 深圳安泰维生物医药有限公司 一种三嗪类化合物及其用途
AU2023249953A1 (en) 2022-04-08 2024-10-24 Shionogi & Co., Ltd. Uracil derivative having viral growth inhibitory activity and pharmaceutical composition containing same
CN116969995A (zh) 2022-04-29 2023-10-31 北京凯因科技股份有限公司 3cl蛋白酶抑制剂
CN117069705A (zh) 2022-05-09 2023-11-17 嘉兴安谛康生物科技有限公司 用于抗新型冠状病毒治疗的1,3,5-三嗪-2,4-二酮衍生物
CN116768867B (zh) 2022-05-19 2026-04-14 深圳安泰维生物医药有限公司 一种三嗪类衍生化合物及其用途
CN117088869A (zh) 2022-05-20 2023-11-21 上海翊石医药科技有限公司 一种3cl蛋白酶抑制剂及其制备方法和应用
CN117126141A (zh) 2022-05-25 2023-11-28 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物及其制备和应用
CN117126137B (zh) 2022-05-27 2025-08-05 广州国家实验室 3c样蛋白酶抑制剂
CN119698410A (zh) 2022-05-27 2025-03-25 广州国家实验室 3c样蛋白酶抑制剂
CN119255987A (zh) 2022-05-27 2025-01-03 广州国家实验室 3c样蛋白酶抑制剂
KR102731073B1 (ko) 2022-06-21 2024-11-15 한국화학연구원 퀴놀론계 유도체, 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 항바이러스용 조성물
WO2024010585A1 (en) 2022-07-07 2024-01-11 Yale University Non-covalent inhibitors of the main protease of sars-cov-2 and methods of use
US20240025885A1 (en) 2022-07-08 2024-01-25 Ascletis BioScience Co., Ltd Triazine derivatives and methods of use thereof
WO2024008909A1 (en) 2022-07-08 2024-01-11 Janssen Pharmaceutica Nv Inhibitors of coronavirus
CN116496266A (zh) 2022-07-08 2023-07-28 歌礼生物科技（杭州）有限公司 三嗪衍生物
CN117402185A (zh) 2022-07-14 2024-01-16 广东东阳光药业股份有限公司 三嗪类化合物及其在药物中的应用
WO2024017178A1 (en) 2022-07-18 2024-01-25 Avitar Biosciences, Inc. Substituted hydantoin compounds, pharmaceutical compositions, and therapeutic applications
CN117430590A (zh) 2022-07-20 2024-01-23 江苏恒瑞医药股份有限公司 环丙基类化合物、其制备方法及其在医药上的应用
CN117466873B (zh) 2022-07-29 2026-06-26 广东东阳光药业股份有限公司 嘧啶类化合物及其在药物中的应用
CR20250040A (es) * 2022-08-05 2025-03-18 Gilead Sciences Inc Inhibidores de la proteasa principal de sars-cov2
CN115894504A (zh) 2022-10-21 2023-04-04 深圳信立泰药业股份有限公司 一种冠状病毒3cl蛋白酶抑制剂及其用途
CN115894443B (zh) 2022-11-17 2024-03-29 上海市重大传染病和生物安全研究院 一种化合物艾奎斯韦及其应用
CN115504968B (zh) 2022-11-21 2023-04-18 歌礼生物科技（杭州）有限公司 三嗪衍生物
CN116041349B (zh) 2022-12-27 2023-10-20 吉斯凯(苏州)制药有限公司 一种黄嘌呤类化合物及其制备方法和在制备新冠病毒3cl蛋白酶抑制剂中的应用
CN116554153B (zh) 2023-04-24 2025-05-16 中国人民解放军军事科学院军事医学研究院 叔酰胺类化合物及其医药用途
CN116621817B (zh) 2023-07-20 2023-09-29 爱斯特（成都）生物制药股份有限公司 一种富马酸恩赛特韦的晶型及其制备方法、药物组合物和用途
AU2025219283A1 (en) * 2024-02-07 2026-08-06 Gilead Sciences, Inc. Sars-cov2 main protease inhibitors

Also Published As

Publication number Publication date
CA3263377A1 (en) 2024-02-08
JP2025525948A (ja) 2025-08-07
CO2025001287A2 (es) 2025-02-24
CL2025000338A1 (es) 2025-07-04
TW202408511A (zh) 2024-03-01
US20250042915A1 (en) 2025-02-06
IL318656A (en) 2025-03-01
CL2025003943A1 (es) 2026-05-15
MX2025001407A (es) 2025-04-02
PE20250877A1 (es) 2025-03-28
US20240239807A1 (en) 2024-07-18
US20240116946A1 (en) 2024-04-11
US12410183B2 (en) 2025-09-09
EP4565574A1 (en) 2025-06-11
KR20250046274A (ko) 2025-04-02
WO2024031089A1 (en) 2024-02-08
CN119731159A (zh) 2025-03-28
AU2023320566A1 (en) 2025-02-20
US12091420B2 (en) 2024-09-17
DOP2025000019A (es) 2025-04-08

Similar Documents

Publication Publication Date Title
CO2025001287A2 (es) Inhibidores de la proteasa principal de sars-cov2
JOP20230138A1 (ar) مثبطات prmt5
DOP2022000183A (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
BR112023025358A2 (pt) Inibidores de protease como antivirais
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
BR112023026976A2 (pt) Inibidores do inflamassoma nlrp3
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
CL2025001961A1 (es) Compuestos y métodos para el tratamiento de infecciones virales
BRPI1014783A2 (pt) formulações farmacêuticas e métodos para tratar infecções do trato respiratório
BR112015005347A2 (pt) composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids
CR20250205A (es) Derivados de 2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopirrolidin-3-il) butan-2-il) benzamida como inhibidores de proteasa para tratar o prevenir la infección por coronavirus.
CY1111102T1 (el) 2-(4-κυανοφαινυλ)-6-υδροξυλαμινοπυριμιδινες που αναστελλουν τον hiv
UY39313A (es) Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire
MX2023014704A (es) Inhibidores de proteasa para el tratamiento de infecciones por coronavirus.
MX2023003846A (es) Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo.
EP4635494A3 (en) AMIDO HETERO-ROMATIC COMPOUNDS
AR132166A1 (es) Inhibidores de inflamasoma nlrp3 y usos de los mismos
MX2024010671A (es) Compuestos antivirales y metodos de elaboracion y uso de los mismos.
JOP20230275A1 (ar) معدلات trex1
CL2022002490A1 (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
BR112022019245A2 (pt) Inibidores de catepsina para prevenir ou tratar infecções virais
CO2023017151A2 (es) Inhibidores de ripk1 de nicotinamida
AR083780A1 (es) Composicion farmaceutica para tratar infecciones del hcv
AR130124A1 (es) Inhibidores de la proteasa principal del sars-cov2